Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3 Year Outcome

Abstract

INTRODUCTION[|]The purpose of this study is to report our functional and anatomical results of intravitreal ranibizumab (IVR) for choroidal neovascularization secondary to pathological myopia (mCNV).[¤]METHODS[|]In this retrospective study, 32 mCNV patients' 32 eyes were evaluated. After one IVR injection patients were followed by an as-needed monthly regime. Best-corrected visual acuity (BCVA) and optic coherence tomography (OCT) findings were evaluated at baseline and then monthly. Re-injection criteria were; reduction in visual acuity and/or increase in central macular thickness measured with OCT.[¤]RESULTS[|]The mean age of the subjects was 57.7+-14.6 years, and the mean axial length was 27.8+-1.3 mm. Mean visual acuity improved significantly from 46.4+-9.7 letters at baseline to 54.1+-9.5 letters at last follow-up visit (p0.05). The average number of injections was 3.5+-1,1, 2.3+-0.9 and 1.7+-0.8 injections at 12, 24 and 36 months respectively. [¤]DISCUSSION AND CONCLUSION[|]This study has shown that IVR injections provide a significant long-term visual and anatomical benefit in mCNV with a small number of injections. [¤]

Keywords

• central macular thickness
• intravitreal ranibizumab
• myopic choroidal neovascularization.